Centre of Cardiology and Cardiovascular Surgery, University Hospital Eppendorf, Hamburg, Germany.
Am J Hypertens. 2010 Jul;23(7):716-24. doi: 10.1038/ajh.2010.78. Epub 2010 Apr 15.
The augmentation index at a heart rate of 75 beats/min (AIx@HR75) and central pulse pressure (CPP) can be measured noninvasively with applanation tonometry (APT). In this observational study, we investigated the relationship between AIx@HR75, CPP and aortic disease in patients with Marfan-like syndromes.
We performed APT in 78 consecutive patients in whom classic Marfan syndrome (MFS) had been excluded (46 men and 32 women aged 34 +/- 13 years). These patients comprised 9 persons with MFS-like habitus, 6 with a bicuspid aortic valve (BAV), 5 with MASS phenotype, 3 with vascular type of Ehlers-Danlos syndrome (EDS), 3 with familial thoracic aortic aneurysm, 2 with Loeys-Dietz syndrome (LDS), 1 with mitral valve prolapse syndrome, 1 with familial ectopia lentis, and 48 persons with Marfan-like features but no defined syndrome. During 20 +/- 18 months after APT, we observed progression of aortic diameters in 15 patients, and aortic surgery or aortic dissection in 3 individuals.
All 11 patients with Marfan-like syndromes and progression of aortic disease exhibited AIx@HR75 > or =11%, including 8 individuals with aortic diameters < or =95th percentile of normal at baseline. Similarly, all 7 individuals without any defined syndrome but progression of aortic diameters exhibited AIx@HR75 >11%, including 6 individuals with aortic diameters < or =95th percentile at the time of APT. Aortic disease did not evolve at AIx@HR75 <11%. CPP is also related to aortic disease progression.
Aortic disease evolution relates to AIx@HR75 and CPP in Marfan like syndromes. Larger studies with comprehensive clinical and echocardiographic follow-up over long time intervals will be required to establish APT for prediction of aortic disease evolution in Marfan-like syndromes.
心率为 75 次/分时的增强指数(AIx@HR75)和中心脉搏压(CPP)可以通过平板压力测量法(APT)进行无创测量。在这项观察性研究中,我们研究了 AIx@HR75、CPP 与马凡样综合征患者主动脉疾病之间的关系。
我们对 78 例连续患者进行了 APT,这些患者已排除了典型马凡综合征(MFS)(46 名男性和 32 名女性,年龄 34 ± 13 岁)。这些患者包括 9 名马凡样体型患者、6 名二叶式主动脉瓣(BAV)患者、5 名 MASS 表型患者、3 名血管型埃勒斯-当洛斯综合征(EDS)患者、3 名家族性胸主动脉瘤患者、2 名洛伊兹-迪茨综合征(LDS)患者、1 名二尖瓣脱垂综合征患者、1 名家族性晶状体异位患者和 48 名马凡样特征但无明确综合征的患者。在 APT 后 20 ± 18 个月期间,我们观察到 15 例患者的主动脉直径进展,3 例患者接受了主动脉手术或主动脉夹层。
所有 11 例马凡样综合征且主动脉疾病进展的患者均存在 AIx@HR75≥11%,包括 8 例基线时主动脉直径<95%正常上限的患者。同样,所有 7 例无明确综合征但主动脉直径进展的患者 AIx@HR75>11%,包括 6 例 APT 时主动脉直径<95%正常上限的患者。AIx@HR75<11%时主动脉疾病未进展。CPP 也与主动脉疾病进展有关。
马凡样综合征中,主动脉疾病的进展与 AIx@HR75 和 CPP 相关。需要进行更大规模的研究,对马凡样综合征患者进行全面的临床和超声心动图随访,以确定 APT 能否预测主动脉疾病的进展。